India’s Aurobindo Gets U.S. FDA Warning Letter For Antibiotics Plant
This article was originally published in PharmAsia News
Executive Summary
Aurobindo Pharma of India reports it has received a warning letter from the U.S. FDA for its Hyderabad facility that produces antibiotics